Cyhoeddiad
2026
- Ingram, J. R. et al. 2026. HiSQOL-mini: Development and validation of a shortened version of the hidradenitis suppurativa quality of life (HiSQOL) instrument. British Journal of Dermatology ljag468. (10.1093/bjd/ljag468)
2025
- Schmidlin, T. et al., 2025. MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens. Cell Reports Methods 101120. (10.1016/j.crmeth.2025.101120)
2024
- Hasan, S. B. et al. 2024. Feasibility of daily pain measurement using text messages in Hidradenitis Suppurativa clinical trials; Data from THESEUS study. British Journal of Dermatology 190 (5), pp.775-777. ljae057. (10.1093/bjd/ljae057)
2023
- James, J. F. et al., 2023. Demographic gaps and requirements for participation: A systematic review of clinical trial designs in Hidradenitis Suppurativa. Dermatology 239 , pp.45-51. (10.1159/000526069)
2022
- Hasan, S. et al. 2022. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa. British Journal of Dermatology 187 (6), pp.846-854. (10.1111/bjd.21821)
2021
- Hasan, S. B. et al. 2021. British Association of Dermatologists (BAD) national clinical audit on the management of Hidradenitis Suppurativa (HS) in the UK. Clinical and Experimental Dermatology 46 (6), pp.1023-1027. (10.1111/ced.14598)
2020
- Hasan, S. and Ingram, J. 2020. What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?. British Journal of Dermatology 183 (5), pp.973-975. (10.1111/bjd.19302)
- Hasan, S. , Ali, F. and Ingram, J. 2020. Cholinergic pruritus responding to Omalizumab. Clinical and Experimental Dermatology 45 (2), pp.264-266. (10.1111/ced.14052)
Erthyglau
- Ingram, J. R. et al. 2026. HiSQOL-mini: Development and validation of a shortened version of the hidradenitis suppurativa quality of life (HiSQOL) instrument. British Journal of Dermatology ljag468. (10.1093/bjd/ljag468)
- Schmidlin, T. et al., 2025. MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens. Cell Reports Methods 101120. (10.1016/j.crmeth.2025.101120)
- Hasan, S. B. et al. 2024. Feasibility of daily pain measurement using text messages in Hidradenitis Suppurativa clinical trials; Data from THESEUS study. British Journal of Dermatology 190 (5), pp.775-777. ljae057. (10.1093/bjd/ljae057)
- James, J. F. et al., 2023. Demographic gaps and requirements for participation: A systematic review of clinical trial designs in Hidradenitis Suppurativa. Dermatology 239 , pp.45-51. (10.1159/000526069)
- Hasan, S. et al. 2022. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa. British Journal of Dermatology 187 (6), pp.846-854. (10.1111/bjd.21821)
- Hasan, S. B. et al. 2021. British Association of Dermatologists (BAD) national clinical audit on the management of Hidradenitis Suppurativa (HS) in the UK. Clinical and Experimental Dermatology 46 (6), pp.1023-1027. (10.1111/ced.14598)
- Hasan, S. and Ingram, J. 2020. What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?. British Journal of Dermatology 183 (5), pp.973-975. (10.1111/bjd.19302)
- Hasan, S. , Ali, F. and Ingram, J. 2020. Cholinergic pruritus responding to Omalizumab. Clinical and Experimental Dermatology 45 (2), pp.264-266. (10.1111/ced.14052)